Plus Therapeutics (PSTV) Long-Term Investments (2010 - 2025)

Plus Therapeutics (PSTV) reported Long-Term Investments of $4.6 million for Q2 2025, up 31.43% quarter-over-quarter from $3.5 million in Q4 2024.

Plus Therapeutics (PSTV) Long-Term Investments (2010 - 2025) Analysis & Trends

Plus Therapeutics (PSTV) has 6 years of Long-Term Investments data on file, last reported at $4.6 million in Q2 2025.

Long-Term Investments for Q2 2025 came in at $4.6 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was $4.6 million (changed N/A YoY), and the FY2024 annual result was $3.5 million, changed N/A from the prior year.
Long-Term Investments advanced to $4.6 million in Q2 2025 per PSTV's latest filing, from $3.5 million in the prior quarter.
Over five years, Long-Term Investments peaked at $4.6 million in Q2 2025 and troughed at $696000.0 in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-	5.17 Mn
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn	5.75 Bn
9	Abivax	94.37 Bn	94.37 Bn	-	-
10	Plus Therapeutics	37.48 Mn	22.37 Mn	-	-

Download Data